A drug developed by researchers at the Renaissance School of Medicine at Stony Brook University that targets enzymes involved in the development of pancreatic cancer cells is showing promise for improved treatment of metastatic pancreatic cancer.
Danbury Hospital and Norwalk Hospital received approval to join NRG Oncology as primary clinical research sites. This means that patients at Danbury Hospital and Norwalk Hospital now have expanded access to the latest clinical trials for breast cancer, radiation oncology, and gynecologic cancer.
Researchers have decoded a chain of molecules that are critical for the growth and survival of pancreatic ductal adenocarcinoma—the most common and also the most lethal form of pancreatic cancer.
Ground-breaking immune therapy promises to deliver vital evidence in the fight against cancer as researchers from the Centre for Cancer Biology open a new clinical trial using genetically engineered immune cells to treat solid cancers.
Mount Sinai researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies, according to results of a clinical trial published in The New England Journal of Medicine in August.
A next-generation clinical trial program and the first-ever adaptive platform trial for brain cancer, GBM AGILE is a move away from the traditional, one-size-fits-all approach to clinical trials – a major step forward for Precision Medicine.
MD Anderson researchers find tumor microbiome influences immune response and patient survival in pancreatic cancer. Study points to fecal transplant as possible treatment.
In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.
Bolstered by more than $37 million in renewed funding from the National Institutes of Health, four institutions in The University of Texas System, along with Rice University, are partnering to expand clinical and translational research, producing better health outcomes for those in Texas and across the nation.
The George Washington University Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma.
The Executive Committee of the Congress of Neurological Surgeons (CNS) voted unanimously during its winter Executive Committee meeting to approve a $1 million gift to the Congress of Neurological Surgeons Foundation (CNS Foundation). The CNS Foundation’s mission is to improve worldwide patient health by supporting innovative programs that allow neurosurgeons to collaborate globally as researchers, learners, educators and caregivers.
The pivotal trial to determine the safety and effectiveness of a modular device designed to be the first completely off-the-shelf endovascular solution for aortic aneurysms involving the visceral branch vessels is successfully underway with its first surgery at UNC Hospitals in Chapel Hill, NC.
The first surgery in New Jersey using the ROSA Brain robot was performed by Ronald Benitez, MD, chief of endovascular neurosurgery, Overlook Medical Center. Conventional brain surgery for epilepsy requires a craniotomy. Using ROSA Brain, surgeons make tiny holes in the skull through which they insert electrodes to record brain activity and help pinpoint exactly which part of the brain is responsible for seizures. The robot can also assist in deep brain stimulation, trans-nasal and ventricular endoscopy, and brain biopsies.
Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the effectiveness of these studies. Researchers designed and tested a new computerized solution that used artificial intelligence (AI) to effectively identify eligible subjects from Electronic Health Records (EHRs), allowing busy clinical staff to focus their limited time on evaluating the highest quality candidates
The NIAID has awarded the University of Alabama at Birmingham Department of Pediatrics a $10. million contract to conduct a multicenter, multinational natural history study of acute flaccid myelitis (AFM) in pediatric patients.
Researchers at the Icahn School of Medicine at Mount Sinai have developed a novel vaccine consisting of DNA and recombinant proteins⸺proteins composed of a portion of an HIV protein and another unrelated protein.
This study, co-led by Samantha Meltzer-Brody, MD, MPH, director of the UNC Perinatal Psychiatry Program, and Daisy Singla, PhD, assistant professor of psychiatry at University of Toronto and clinician scientist at Sinai Health System, will investigate how to make talk therapy treatment – specifically behavioral activation – more accessible to all women.
A highly competitive $4.5 million grant from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) will support Keck School of Medicine of USC efforts to recruit patients from underrepresented populations into cardiac surgery clinical trials.
SimPHARM is a clinical therapeutic simulation tool that creates a realistic clinical experience in which one minute of virtual time equals one minute of real time. Ideal for flipped classroom learning environments, the platform's cognitive game engine empowers students to develop their clinical decision-making skills at their own pace while under the supervision of faculty. It is built on mathematical models of the physiology of body systems that simulates real life reactions to diseases and drugs. This allows the student to sense and feel the consequences of their decisions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bio-Rad’s IH-500, an automated random access system for blood typing and screening.
A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine. The drug, rimegepant, is awaiting U.S. Food and Drug Administration approval and may offer advantages over currently available migraine medications. The study was led by researchers at Albert Einstein College of Medicine and Montefiore Health System.
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients. Over 850 million people suffer from kidney diseases worldwide, a number which signifies epidemic proportions, yet these patients are still ignored by investigators and initiators of clinical trials in all medical fields – and are thus excluded from clinical trials. ASN, ERA-EDTA and ISN, collaboratively aim to bring about a paradigm change in medical research and have launched an information campaign to that end.
Patients with sickle cell disease experience severe organ damage leading to early death. An international clinical trial funded by the NIH will test whether red cell exchange, which replaces sicked red blood cells with normal ones could prevent or reverse organ damage and prolong life.
In the first clinical trial of its kind, researchers hope to discover whether following the ketogenic diet will help patients with acute spinal cord injuries regain sensory and motor functions faster than those who do not follow the diet.
The males of one species of butterfly are more attracted to females that are active, not necessarily what they look like, according to a recent research conducted at Augustana University.The paper, “Behaviour before beauty: Signal weighting during mate selection in the butterfly Papilio polytes,” found that males of the species noticed the activity levels of potential female mates, not their markings.
Suicide and attempt rates are greatly elevated among patients after discharge from psychiatric hospitalization – especially during the first year after discharge, concludes a research review in the July/August issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Irvine, Calif., July 8, 2019 — University of California, Irvine researchers have developed and tested on mice a therapeutic treatment that uses engineered stem cells to target and kill cancer bone metastases while preserving the bone. This new approach, reported in the journal EBioMedicine, equips engineered mesenchymal stem cells with targeting agents that drive them to bone metastatic sites, where they offload therapeutics.
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Intermountain Healthcare has earned top accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for ensuring the highest protections for participants in Intermountain clinical research studies.
Decisions to prescribe children drugs to treat chronic pain are not guided by sufficient, high quality evidence, according to an important new study published today (Wednesday 26 June 2019).
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that individuals reported more gastrointestinal bloating when they ate a diet high in salt.
Three abstracts focused on improving clinical trials processes have been selected for formal presentation at the Association of American Cancer Institutes’ Clinical Research Innovation annual meeting, July 9-11, in Chicago.
Hackensack Meridian Health Ocean Medical Center Foundation raised nearly $250,000 at the 29th Annual Golf Classic, which took place on June 17 at Manasquan River Golf Club in Brielle. This year’s event welcomed 120 golfers who competed in the tournament to raise money for programs and services at Hackensack Meridian Health Ocean Medical Center.
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients. The researchers sought to identify potential interventions – i.e., solutions – to improve the situation.
Multi-institution collaboration is the first in the western U.S. to perform completely laparoscopic repair of open spina bifida
University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
Issues like age or existing arthritis may preclude patients from participating in clinical studies for new therapies that could benefit them
BOSTON – (June 11, 2019) – Researchers from Joslin Diabetes Center, using a genome-wide association study, have identified a genetic factor linked to the development of diabetic peripheral neuropathy. This finding suggests a new target for preventive therapies. The research has been published online and will appear in the August print issue of Diabetes.
L’Institut et hôpital neurologiques de Montréal (le Neuro) dirigera un partenariat en science ouverte en vue de la mise au point de médicaments de précision indiqués dans la sclérose latérale amyotrophique (SLA) et la maladie de Parkinson (MP).
The Neuro (Montreal Neurological Institute and Hospital) will lead an open science partnership to develop precision drugs for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
When prescribed the anticoagulant drug warfarin, many patients are told to limit foods rich in vitamin K, such as green vegetables. The results of a new clinical trial call that advice into question and suggest patients on warfarin actually benefit from increasing their vitamin K intake—as long as they keep their intake levels consistent.
AMP has revised its official position for all consumer genomic testing. Based on a recent assessment of the current market landscape and privacy best practices, the latest position statement features an expanded list of conditions that must be met before AMP can support a clinically-meaningful test.
A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes. During more than five years of follow-up, cardiovascular events like heart attacks and strokes were reduced by 12% in people taking dulaglutide compared to people taking a placebo. This effect was seen in both men and women with or without previous cardiovascular disease.
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL).
Results of a phase 3 clinical trial by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that women with HER2-positive breast cancer had significantly better response rates, but more severe side effects, when they were treated with traditional neoadjuvant chemotherapy along with dual HER2-targeted blockade, compared to a more novel approach using HER2-targeted chemotherapy plus HER2-targeted blockade.
There are no approved treatment options for patients with advanced bladder cancer after standard chemotherapy and immune treatments, but the results of a phase II clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers demonstrates an effective treatment for this deadly disease.
Georgetown University Medical Center announces the launch of the only known therapeutic (disease modifying) clinical trial for Lewy body dementia, a neurological disorder that affects a million people in the United States for which there are no approved medications that modify the disease.
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center.
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers. This publication accompanies a presentation today that outlines the study results at the American Society for Clinical Oncology (ASCO). Researchers found that treatment with apalutamide significantly improved overall survival, with a 33% reduction in risk of death compared to standard-of-care therapy. Additionally, this study showed apalutamide significantly delayed disease progression and increased the amount of time until a patient has to receive chemotherapy.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right